中晚期卵巢癌恩度联合TP方案化疗的近期疗效观察

THE STUDY OF RH-ENDOSTAIN CONBINED WITH TP REGIMEN ON ADVANCED OVARIAN CANCER PATIENTS

目的:研究比较在晚期卵巢癌中紫杉醇联合奈达铂同步恩度治疗与单纯紫杉醇联合奈达铂的疗效和不良反应。方法:36例经病理学证实的中晚期卵巢癌病人,随机分为两组:试验组(恩度静脉滴注+紫杉醇联合奈达铂化疗)18例,对照组(单纯紫杉醇联合奈达铂化疗)18例。比较治疗前、治疗2周期、治疗4周期后血清CA 125、肿瘤大小变化,并观察两组不良反应的发生率,评价临床疗效和安全性。结果:两组均完成治疗,2周期后恩度组的有效率为38.9%,对照组有效率为22.2%,两组之间具有统计学差异(P<0.05),4周期后有效率分别为50.2%和30.1%,差异亦有统计学意义。对两组不良反应情况进行比较,主要为骨髓抑制、消化道反应为主,两组差异无统计学意义(P>0.05),心脏毒性,试验组略多于对照组,但差异无统计学意义。结论:恩度联合TP方案治疗中晚期卵巢癌疗效确切,不良反应轻,值得推广应用。

Objective:To study the efficacy and safety of rh-endostain(endostar)combined with TP regimen(paclitaxel plus nedaplatin)on patients with advanced ovarian cancer.Methods:A retrospective analysis of 36 cases of advanced ovarian cancer patients confirmed by histopathology or cytopathology,were compared,treated from 2012-10 to 2015-05 in our hospital.It was randomly divided into two groups;one group of 18 cases was given paclitaxel plus nedaplatin combined with rh-endostain(trial group),another of 18 cases was treated only by paclitaxel plus nedaplatin(control group).endostar)combined with TP scheme:endostar 15 mg/d,d 1-14,paclitaxel 135~175 mg/m 2,d 1,nedaplatin 60~80 mg/m 2 d 1;paclitaxel and nedaplatin scheme:paclitaxel 135~175 mg/m 2,d 1,nedaplatin 60~80 mg/m 2 d 1;Tumor size were measured before and after two cycles,and after four cycles of treatment between both group.The incidence of adverse reactions of two groups of observation was collected in 1months after the end by reviewing the clinical efficacy of CT.Results:Two groups were completed the treatment,after 2 cycles,RR of paclitaxel and nedaplatin combined with endostar group was 38.9%,RR of control group was 22.2%,with statistically significant difference between the two groups(P<0.05).While those were 50.2%and 30.1%after four cycles treatment,the efficacy of the paclitaxel and nedaplatin combined with endostar group was better than the contral group(P<0.01).To compare the two groups of adverse reactions,mainly for bone marrow transplantation,digestive tract reaction,andcardiovascular toxicity.All of the difference was no statistically significant(P>0.05).Conclusion:The curative effect of clinical application of paclitaxel plus nedaplatin combined with endostar in treatment of advanced ovarian cancer is accurate,less adverse reactions,it is worthy of popularization and application.